This segment focuses on the development and commercialization of spatial biology tools, including the GeoMx Digital Spatial Profiler (DSP) system and related assays. Research and development activities include continuous improvement of the DSP platform, development of new assays for various applications, and integration with advanced imaging and analysis tools. The GeoMx DSP enables researchers to analyze gene expression and protein expression in a spatially resolved manner, providing insights into the tumor microenvironment, immune cell interactions, and other biological processes. This technology is used in oncology, immunology, and neuroscience research, with applications in drug discovery, biomarker identification, and clinical trials. The patient impact is significant, as these tools help researchers understand disease mechanisms and identify potential therapeutic targets. Market positioning is strong due to the unique capabilities of spatial profiling, and the company has collaborations with leading research institutions and pharmaceutical companies. Future opportunities include expansion into new therapeutic areas and the development of companion diagnostics. Regulatory and clinical aspects are relevant as the company seeks to validate its assays for clinical use. Partnerships with contract research organizations (CROs) and core labs are crucial for expanding the reach of the technology.

This segment encompasses the nCounter Analysis System, a digital detection and counting platform used for a wide range of applications in genomics and proteomics research. R&D efforts focus on improving the system's performance, expanding the assay menu, and developing new software for data analysis. The nCounter system utilizes a unique digital barcode technology to directly count individual molecules, providing highly sensitive and reproducible results. It is used in oncology, immunology, infectious disease, and neuroscience research, enabling researchers to profile gene expression, detect protein expression, and analyze other molecular targets. The patient impact is realized through improved understanding of disease mechanisms and the identification of biomarkers for diagnosis and prognosis. The nCounter system has a strong market position due to its ease of use, multiplexing capabilities, and ability to analyze a wide range of sample types. Future opportunities include expansion into new applications, such as liquid biopsy and single-cell analysis. The company also offers custom CodeSets and Master Kits to support researchers' specific needs. Partnerships with research institutions and pharmaceutical companies are key to driving adoption and expanding the system's applications.